CSChalairat Suk-Ouichai

Chalairat Suk-Ouichai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chalairat Suk-Ouichai has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characteristic Findings in Aborted Robot-Assisted Radical Prostatectomies

    by Kathryn E. Fink, Austin Drysch, Nicole Handa, Mitchell Huang, Sai Kumar, Yutai Li, Chalairat Suk-Ouichai, Kent T. Perry, Ridwan Alam, Hiten D. Patel, et al.

    Background: In rare instances, patients deemed operative candidates for robot-assisted radical prostatectomy (RARP) have their procedure aborted intraoperatively. Understanding the incidence and factors associated with aborted RARP cases can improve preoperative counseling and intraoperative decision-making. We performed a retrospective analysis of RARP cases performed by high-volume surgeons across our multihospital medical system to characterize the incidence and causes of aborted procedures. Methods: We queried the Northwestern Electronic Data Warehouse from January 2018 to June 2024 for patients who underwent RARP performed by high-volume surgeons. Aborted procedures were defined as those terminated after anesthesia but before completion. Comparative statistics were used to evaluate clinical, radiologic, and pathologic characteristics between aborted and completed cases. Imaging features of propensity-matched patients with completed or aborted procedures were also analyzed. Results: Among 3316 RARPs performed by 10 high-volume surgeons, 26 cases (0.7%) were aborted. The leading causes were pelvic lipomatosis (35%), adhesions (27%), and cardiorespiratory events (12%). Higher body mass index (BMI) was significantly associated with aborted operation (30.7 vs 27.8, p = 0.015). Although prior abdominal operations were more frequent in the aborted group (7.7% vs 2.6%), this was not statistically significant ( p = 0.2). Perioperative complications occurred in 12% of aborted cases. Four cases were reattempted, with three completed effectively. The apparent diffusion coefficient of perivesical pelvic fat was higher in aborted cases but not statistically significant ( p = 0.13). Conclusions: The incidence of aborted RARP among experienced surgeons is low, accounting for less than 1% of all cases. Pelvic lipomatosis was the most common reason for an aborted procedure and may be recognized preoperatively on imaging. Higher BMI was associated with a significantly higher risk for aborted procedure. When counseling patients, this information could be used to set expectations for the risk of an aborted procedure.

  • Open Access

    CT volumetric analysis: association of renal parenchyma and GFR alteration in nephrectomy patients

    by Wasin Saengthongpithak, Chalairat Suk-Ouichai, Tawatchai Taweemonkongsap, Shanigarn Thiravit, Ekkarin Chotikawanich, Siros Jitpraphai, Varat Woranisarakul, Katunyou Mahamongkol, Thitipat Hansomwong

  • Open Access

    Utilization of cardiopulmonary bypass at radical nephrectomy for renal cell carcinoma with tumour thrombus

    by Chalairat Suk‐Ouichai, Mitchell M. Huang, Clayton Neill, Christopher K. Mehta, Ashley E. Ross, Shilajit D. Kundu, Kent T. Perry, Duc T. Pham, Hiten D. Patel

    Objectives: The objective of this study is to evaluate preoperative factors associated with cardiopulmonary bypass (CPB) utilization and outcomes for patients with renal cell carcinoma (RCC) and tumour thrombus (TT). Radical nephrectomy with thrombectomy is a standard treatment for patients with RCC and associated TT. Morbidity and mortality rates tend to correlate with aggressiveness of tumour and TT level.Methods: Patients undergoing radical nephrectomy with thrombectomy (2006–2023) were retrospectively identified. Inclusion criteria included RCC histology and preoperative imaging available for thrombus‐level categorization based on the Mayo Clinic grading system. Logistic regression assessed predictors for utilizing CPB, and Cox regression identified factors associated with survival.Results: A total of 72 patients with RCC and associated TT were identified. The median age was 67 years. RCC‐related symptoms were present in 83%, and 28% had Levels 3 and 4 thrombi. Eleven patients (15.3%) had undergone neoadjuvant therapy, and 81% had clear‐cell RCC. CPB was utilized in eight (11.1%) cases. The median tumour size was 10.5 cm. Metastatic disease was greater in the CPB cohort (75% vs. 28%, p = 0.008). All cases performed on CPB were Levels 3 and 4 thrombi (100% vs. 19% in the non‐CPB group, p < 0.001). CPB cases had significantly longer operative time, and hospital stays and rates of Clavien ≥ 3 complications. On multivariate analysis, metastatic disease was a predictor of CPB utilization. Median survival was 74 and 25 months in the non‐CPB and CPB cohorts, respectively (p = 0.01). Pulmonary disease and metastatic disease with CPB utilization were significantly associated with worse survival on multivariate analysis.Conclusions: Surgical extirpation of kidney tumours with associated TT remains the standard of care among patients with locally advanced RCC. CPB can be utilized to increase the feasibility of resection for high‐level thrombi. Preoperative planning and cooperation among surgical teams are key given the perioperative morbidity and mortality.


  • Open Access

    Treatment Modalities and Risks of Complication for Patients With Localized Renal Cell Carcinoma Aged 75 and Older

    by Chalairat Suk‐Ouichai, Hiten D. Patel, Kent T. Sato, Shilajit D. Kundu, Ashley E. Ross, Kent T. Perry

    Background and Objectives: Partial (PN)/radical (RN) nephrectomy is the standard treatment for localized renal‐cell carcinoma (RCC). The potential risks of these procedures are concerns for the elderly. We evaluated perioperative outcomes/survival for patients aged ≥ 75 years with localized RCC who underwent PN, RN, or thermal ablation (TA). Methods: Localized RCC patients undergoing PN/RN/TA (2000–2023) were retrospectively reviewed. Logistic‐regression assessed factors associated with major complications. Kaplan‐Meier estimated survival. Results: A total of 278 patients (≥ 75 years) with RCC who received intervention (107RN, 101PN, and 70TA) were identified. Median age was 78 years. PN patients were younger than other cohorts (77 vs. 79, p = 0.006). Patients with cancer comorbidities underwent TA than PN/RN (93% vs. 88%/76%, respectively). Median tumor size was 4.0, 3.0, and 2.6 cm in RN, PN, and TA cohorts, respectively. RN patients had more complex masses compared to other cohorts (9 vs. 7, p < 0.001). Postoperative complications were significantly greater among PN patients ( p = 0.03), but there was no significant difference in Clavien ≥ 3 complications. Peripheral vascular disease (PVD) was associated with Clavien ≥ 3 complications on multivariable analysis ( p = 0.03). RN was performed at a stable rate while PN decreased in favor of TA. There was no significant difference in RCC‐/non‐RCC‐specific survival among treatment modalities. Conclusions: It is important to make informed decisions about treating RCC in the elderly to reduce morbidity/mortality. PVD could be a determining factor favoring TA for amenable tumors.


  • Open Access

    In vitro Comparison of the Mechanical and Optical Characteristics of 5 Disposable Flexible Ureteroscopes

    by Phirawat Phromprathum, Sittiporn Srinualnad, Sunai Leewansangtong, Tawatchai Taweemonkongsap, Kittipong Phinthusophon, Siros Jitpraphai, Patkawat Ramart, Varat Woranisarakul, Chalairat Suk-Ouichai, Thawatchai Mankongsrisuk, et al.

    Introduction: Disposable (single-use) flexible ureteroscopes are alternatives to reusable ureteroscopes. With their superior surgical efficacy and safety in the presence of upper urinary calculi, disposable ureteroscopes aim to overcome the main limitations of conventional reusable ureteroscopes. However, studies on the performance of the most recently developed models of single-use flexible ureteroscopes are scarce. This study aimed to compare the in vitro performance of several recently introduced, single-use, flexible ureteroscopes. Methods: Five disposable flexible ureteroscopes were tested in vitro to evaluate their mechanical and optical characteristics. To this end, their degrees of deflection, irrigation flow rates, and image qualities were investigated. The models examined were Innovex US31-B12, OTU-100RR, Redpine RP-U-C12, Sciavita SUV-2A-B, and Seplou URS3016E. Their performance was also compared with that of a reusable flexible ureteroscope, Olympus URV-F. Results: The OTU device had the highest degrees of deflection and the smallest loop diameter of the disposable ureteroscopes. The single-use ureteroscopes had identical image resolutions at a distance of 1 cm. The Innovex and Redpine devices had the best color representation. Conclusions: Of the tested disposable ureteroscopes, the OTU device had the best mechanical attributes, given its small loop diameter, high deflection angles, and low irrigation flow loss. As to their optical properties, the resolutions of all 5 single-use models were identical at an image distance of 1 cm.


  • A clinical overview of people living with HIV and genitourinary cancer care

    by Chalairat Suk-Ouichai, Anna E. Coghill, Matthew B. Schabath, Julian A. Sanchez, Jad Chahoud, Andrea Necchi, Anna R. Giuliano, Philippe E. Spiess

    The number of people living with HIV infection has been increasing globally. Administration of antiretroviral therapy is effective in controlling the infection for most patients and, as a consequence, people living with HIV (PLWH) now often have a long life expectancy. However, their risk of developing cancer — most notably virus-related cancers — has been increasing. To date, few studies have assessed the risk of genitourinary cancers in PLWH, and robust scientific data on their treatment-related outcomes are lacking. Previous studies have noted that PLWH are at a reduced risk of prostate cancer; however, low adoption and/or availability of prostate cancer screening among these patients might be confounding the validity of this finding. In genitourinary cancers, advanced stage at diagnosis and reduced cancer-specific mortality have been reported in PLWH. These data likely reflect, at least in part, the inequity of health care access for PLWH. Notably, systemic chemotherapy and/or radiotherapy could decrease total CD4+ cell counts, which could, therefore, increase the risk of morbidity and mortality from cancer treatments in PLWH. Immune checkpoint inhibitors have become the therapeutic backbone for many advanced malignancies in the general population; however, most studies validating their efficacy have excluded PLWH owing to concerns of severe adverse effects from immune checkpoint inhibitors themselves and/or related to their immunosuppressed status. To our knowledge, no genitourinary cancer survivorship programme exists that specifically caters to the needs of PLWH. By including PLWH in ongoing cancer trials, we can gain invaluable insights that will help to improve cancer care specifically for PLWH.


  • Parenchymal Volume Replacement by Renal Cell Carcinoma Prior to Intervention: Predictive Factors and Functional Implications

    by Diego Aguilar Palacios, Rebecca A. Campbell, Yosuke Yasuda, Gustavo Roversia, Carlos Munoz-Lopez, Emily Abramczyk, Maureen Kelly, Elvis R. Caraballo, Chalairat Suk-Ouichai, Lin Lin, et al.


  • Open Access

    Survival Benefits After Surgery of Renal Cell Carcinoma Patients with Inferior Vena Cava Thrombus

    by Tawatchai Taweemonkongsap, Ekkarin Chotikawanich, Siros Jitpraphai, Varat Woranisarakul, Thitipat Hansomwong, Chalairat Suk-Ouichai

    OBJECTIVE: To evaluate surgical and oncological outcomes after surgery in renal cell carcinoma (RCC) patients with inferior vena cava (IVC) tumor thrombus METHODS: A total of 58 patients from 2002 to 2019 underwent radical nephrectomy and IVC thrombectomy at Siriraj Hospital, Bangkok, Thailand, were retrospectively reviewed. Kaplan-Meier analysis was utilized to compare survival benefits between cohorts and Cox regression to evaluate predictors of patient survival. RESULTS: There were 5 (8.6%), 21 (36.2%), 23 (39.7%) and 9 (15.5%) patients with tumor thrombus level I, II, III and IV respectively. The major complications (Clavien 3-5) were observed in 15 patients (25.8%) and 80% were patients with high thrombus level (III-IV). There was 9% mortality (5 patients): 2 intraoperatively and 3 postoperatively. Median follow-up was 15 months (IQR:5-41). Two-year overall survival (OS) was 80% and 75% in all patients and pN0M0 cohort, respectively. There was significant difference in OS among each IVC thrombus level cohort (pCONCLUSION: Our study suggested that surgical treatment for RCC with IVC thrombus provided acceptable OS outcomes, even in a small volume experience. Although the survival was significantly reduced with higher IVC thrombus level cohort, the level of thrombus itself was not an independent factor. Only sarcomatoid dedifferentiation was a predictor for OS after radical nephrectomy and tumor thrombectomy.

  • The Complete Spectrum of Infiltrative Renal Masses: Clinical Characteristics and Prognostic Implications

    by Yanbo Wang, Hajime Tanaka, Yunlin Ye, Xiaobo Ding, Ryan D. Ward, Rebecca A. Campbell, Molly E. DeWitt-Foy, Chalairat Suk-Ouichai, Erick M. Remer, Steven C. Campbell


  • Open Access

    Administration of Renin-Angiotensin System Inhibitor Affects Tumor Recurrence and Progression in Non-Muscle Invasive Bladder Cancer Patients

    by Chalairat Suk-Ouichai, Saran Maneesuwansin, Patkawat Ramart, Siros Jitpraphai, Kittipong Phinthusophon, Ekkarin Chotikawanich, Teerapon Amornvesukit, Tawatchai Taweemonkongsap, Bansithi Chaiyaprasithi, Sunai Leewansangtong, et al.

    Administration of Renin-Angiotensin System Inhibitor Affects Tumor Recurrence and Progression in Non-Muscle Invasive Bladder Cancer Patients